Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line or Third-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)

NCT02363491 is registered in ClinicalTrials.gov with Opsona Therapeutics Ltd. as lead sponsor.

NCT NCT02363491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02363491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line or Third-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)
Lead sponsor
Opsona Therapeutics Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2015
Completion date
December 31, 2018
Enrollment
96 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome